ERBB2 and breast cancer: The Nefmut-based strategy was successfully applied against transplantable tumors expressing TSAs, i.e., HPV-E6 and -E7 [29], as well as against ectopic tumors expressing HER2/neu [30], i.e., a TAA overproduced in a model of a spontaneous mouse mammary tumor.